Industry
Life Sciences
Patient-centered Care Models Taking Center Stage in Life Sciences
Highlights
- Pharmacovigilance has been a compliance mandate for long and so the economic perception has largely been that of a cost overhead than a value creator.
- In tandem with human oversight, AI agents can now transform disparate safety information to intelligence and generate real-world evidence.
- This real-world evidence can enable accelerated decision making across the product life cycle and create value for pharma enterprises.
On this page
On this pageinpage
Introduction
Pharmacovigilance (PV) has all along been a surveillance and compliance functional area. Its measurable success parameters include case-processing quality, reporting timeliness, inspection readiness, and avoidance of regulatory findings. While such measures remain essential, they have created a narrow economic perception of PV as an overhead rather than an enterprise value source. By orchestrating multi-step work backed by human oversight, AI agents can convert fragmented safety information into intelligence. Much larger than automation, the strategic shift is from processing transactions to generating value-based evidence. Such real-world evidence can improve decisions across the entire product lifecycle.
From safety data to an intelligence engine
PV workflows handle data in functional and process silos. Individual case safety reports, clinical data, medical literature, product complaints, medical information interactions, regulatory commitments, electronic health records, and other real-world sources are reviewed at different times, by different teams, for different purposes. The consequence is a rich but underused evidence base. AI Agents can connect these activities while maintaining context across the workflow. Agents can extract relevant information, reconcile discrepancies, identify missing data, and direct information to the right team at the right time. Instead of treating each case as an isolated transaction, an organization can build a longitudinal view of how a medical product performs across patient groups, indications, geographies, comorbidities, concomitant therapies and medications, and healthcare settings.
This creates three new scenarios:
- Case handling evolves to evidence generation: Every validated observation enriches the product’s evolving benefit-risk profile.
- Retrospective review repositions as proactive earlier action: Continuous surveillance can detect emerging patterns, unusual combinations, or vulnerable subpopulations sooner.
- Safety databases become an enterprise data product: Clinical development, regulatory affairs and medical affairs, quality, market access, and various other portfolio teams can reuse governed insights. Measure value not by the volume of data collected, but by the speed and value with which an organization can turn that data into a valid decision.
How does safety intelligence create value?
Secure revenue is the first source of value. Earlier visibility of risk factors and faster mitigation can reduce the likelihood of a manageable issue escalating into a disruptive change in safety profile. Although it does not appear as a new revenue line, it protects the durable value of the marketed asset portfolio.
Data discovery is the second source. More precisely evidence-based data can open the possibility of new benefit-risk profile in specific populations, support dose or formulation changes, strengthen regulatory submissions, and reveal new indications for expansion or differentiated positioning. PV insights can improve protocol design, eligibility criteria, endpoint selection, and risk-management planning when contextualized with clinical and real-world evidence. Avoidable uncertainty can be reduced with better evidence, and valuable assets can reach additional patients faster.
The third source is product performance. Near-real-time understanding of toxicity, adherence, treatment discontinuation, and preventable adverse events and outcomes can strengthen medical knowledge and evidence discussions with regulatory authorities, payers and health care systems. It can also enable more targeted risk-minimization programs. In this model, PV generates valuable safety intelligence that helps other functional areas make stronger data-oriented decisions.
R&D and portfolio productivity are the fourth source of enterprise value. Patterns from investigational and marketed products can advise about molecule selection, dose strategy, trial monitoring, and portfolio prioritization. The bulk of the capital can be allocated to products, indications, or populations with stronger evidence, and assets with a lower probability of success can be allocated less capital. This way, value is created by the identification of opportunities as well as by considering which low-value programs should be considered to continue.
Finally, with the adoption of agents, organizations may create data-based evidence and build partnerships with health care systems, research and academic organizations, and technology partners. The goal is not for PV to become a data broker. It is to create privacy-preserving, contractually authorized insights, analytical methods, and decision-support capabilities that improve evidence generation and patient outcomes.
The PV operating model must change with technology
Bringing agents into the existing PV operations will be transformational and, like all big changes, will also be challenging.
AI-first PV operations will not only increase operational efficiency but will also switch PV into reusable evidence and measurable enterprise outcomes. The function must be organized around a governed human-and-AI workforce. Agents should have defined roles, permissions, tools, escalation criteria, and measurable responsibilities. Humans should remain accountable for medical judgment and safety-critical decisions.
A shared data foundation is essential for the success of this model. Every consequential output should be traceable to its source, reproducible, reviewable, and retained in an audit-ready record. The strongest architecture is a controlled environment in which agents can collaborate across workflows while preserving accountability, and not just a collection of stand-alone agents.
A new scorecard for PV
If PV is to be managed as a value-generating function, its scorecard must extend beyond cost per case, processing turnaround time, and submission timelines. Leaders should track:
- Scientific measures: Such as time to validate signal, evidence completeness, and decision confidence
- Operational measures: Such as throughput, accuracy, rework, exception rates, and cycle time
- Enterprise measures: Such as avoided disruption, time gained in development, lifecycle opportunities supported, and adoption of safety insights by other functions.
From safety data to enterprise value: 8 revenue-enabling scenarios
Value opportunity | Illustrative Scenario | Action | Value impact |
Indication expansion | PV and real-world evidence show a favorable benefit–to-risk profile in an underserved population. | Launch a targeted clinical or regulatory program. | Access to an additional patient population. |
Dose or formulation optimization | Adverse events cluster around a dose, titration schedule, or administration route. | Develop a lower-dose, modified formulation, or an improved regimen. | Better persistence and extended product lifecycle. |
Differentiated safety positioning | Validated comparative evidence demonstrates stronger tolerability. | Support scientific, access, and payer discussions. | Improved formulary position and clinical adoption. |
Early signal detection | An emerging signal and potential population risk are identified early. | Initiate targeted mitigation action before restrictions are required. | Avoided loss and preserved asset value. |
Clinical development productivity | Agent identifies a weak dose, biomarker, or treatment path. | Redesign the protocol or stop a low-probability program earlier. | Capital redirected to higher-value assets. |
Evidence collaboration opportunities | Privacy-preserving analytics or decisions support address partner needs. | Create authorised offerings for health systems, networks, or alliance partners. | Partnership funding, licensing, or shared-value revenue. |
Faster regulatory approval or label expansion | Traceable evidence is assembled faster across trials, cases, literature, and real-world sources. | Accelerate submissions and responses to regulators. | Earlier approval and more months on market. |
Adherence | PV data reveal preventable tolerability drivers of discontinuation. | Introducing evidence-based medical monitoring and education programs. | Improved adherence and outcomes. |
Trust is the key to change
Value creation from PV happens when it is not just autonomous, but where human accountability exists for agentic AI driven operations. Current regulatory direction supports a risk-based approach.
- Begin with targeted, high-impact use cases within bounded workflows where human accountability remains explicit.
- Expand adoption incrementally, moving from assistive and co-pilot led operations to carefully governed autonomous operations as confidence, evidence, and organisational readiness increase.
- The true differentiator is not autonomous agent activity alone, but the ability to govern the entire lifecycle through rigorous validation, versioning, auditability, performance monitoring, access controls, escalation pathways, and human override capabilities.
Final thoughts
Considering current technological developments, the industry’s vision is no longer whether PV can be automated. It is whether PV can become a trustworthy and productive source of intelligence without compromising patient safety and privacy, scientific accuracy, or regulatory accountability. That requires a cross-functional common-value mission definition among PV, clinical development, medical affairs, regulatory, quality, data, technology, privacy, and commercial leadership.
Organizations that make this transition will not simply run PV at a lower cost. They will build systems around products capable of generating value, identifying opportunities, and improving the quality of decisions from development through post-market settings. In the new PV model, patient safety and enterprise growth are not competing objectives.
PV generates value by prudently leveraging governed safety evidence for accelerated decisions, stronger products, expanded access, and avoided loss.
AI agents can reposition pharmacovigilance from a function that records the cost of safety to one that compounds the value of safety data—protecting revenue today, accelerating growth tomorrow, and making patient safety a source of enterprise intelligence and competitive advantage.
AI agents can reposition pharmacovigilance from a function that records the cost of safety to one that compounds the value of safety data.
8 revenue-enabling opportunities enabled by AI-powered pharmacovigilance.